BEGIN:VCALENDAR
VERSION:2.0
PRODID:talks.ox.ac.uk
BEGIN:VEVENT
SUMMARY:Targeting the lymphatics to develop next generation therapies for 
 inflammatory diseases - Dr Natalie Trevaskis (Monash University)
DTSTART;VALUE=DATE-TIME:20260309T150000Z
DTEND;VALUE=DATE-TIME:20260309T160000Z
UID:https://talks.ox.ac.uk/talks/id/2110b981-4424-4e1b-8c93-bee8964c4fab/
DESCRIPTION:The lymphatic vessels were once considered like ‘pipes’ th
 at drain excess fluid\, lipids and immune cells from tissues back to the b
 lood circulation. We now know that lymphatic vessels and lymph nodes are d
 ynamic structures\, constantly changing in response to the surrounding env
 ironment\, communicating with tissues such as fat and actively regulating 
 the transport of molecules and cells to influence health and disease. The 
 lymphatic system has also been found to play an active role in a range of 
 diseases from cancer to inflammatory and metabolic diseases. Join me to he
 ar about our adventures developing new ways to deliver medicines into the 
 lymphatics and better treat metabolic and inflammatory diseases. \n\nBiogr
 aphy: \nNatalie Trevaskis is a Professor\, Pharmacist and Heads the Lympha
 tic Medicine Laboratory at the Monash Institute of Pharmaceutical Sciences
 \, Melbourne\, Australia. Her research program is focussed on the role of 
 lymphatics in acute\, inflammatory and metabolic diseases\, and understand
 ing the delivery of therapeutics and vaccines to the lymphatics to treat t
 hese diseases. She has extensive experience in biopharmaceutics\, pharmaco
 kinetics and delivery of a range of therapeutic types. \n\nNatalie’s res
 earch has resulted in >100 peer reviewed papers (9848 cites) including sig
 nificant papers in Nature\, Nature Metabolism\, Nature Nano\, Nature Rev D
 rug Discovery\, Angew Chemie\, J Control Rel etc. She is also an inventor 
 of 10 patent families (>60 individual patents)\, including for a lymph-dir
 ecting prodrug technology licensed to Seaport Therapeutics with three cand
 idates currently in clinical trials. Natalie has worked and consulted exte
 nsively with industry (Pfizer\, Novartis\, Astra Zeneca\, Eli Lilly\, Amge
 n\, Genentech\, Janssen\, Protagonist\, PureTech Health\, Noxopharm etc.) 
 to solve drug delivery problems. \n\nNatalie has received several notable 
 academic prizes. From 2022-24\, Natalie was named a Clarivate highly cited
  (Hi-Ci) researcher in pharmacology (top 0.1% or ~120 worldwide). She rece
 ived the Vice Chancellor’s Researcher of the Year for Monash University 
 in 2025.\nSpeakers:\nDr Natalie Trevaskis (Monash University)
LOCATION:IMS-Tetsuya Nakamura Building (IDRM Seminar Rooms 1&2 or via Team
 s link)\, Roosevelt Dr\, Headington OX3 7TY
TZID:Europe/London
URL:https://talks.ox.ac.uk/talks/id/2110b981-4424-4e1b-8c93-bee8964c4fab/
BEGIN:VALARM
ACTION:display
DESCRIPTION:Talk:Targeting the lymphatics to develop next generation thera
 pies for inflammatory diseases - Dr Natalie Trevaskis (Monash University)
TRIGGER:-PT1H
END:VALARM
END:VEVENT
END:VCALENDAR